Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Isis gets drug funding

April 17, 2006 | A version of this story appeared in Volume 84, Issue 16

Symphony Capital Partners and a group of coinvestors will provide Isis Pharmaceuticals with $75 million to fund development of Isis' cholesterol-lowering drug, ISIS 301012 (see page 13), and two novel diabetes drugs. As part of the deal, Isis granted a unit of Symphony Capital and its partners a license to the intellectual property for the three drug programs. However, Isis retains the exclusive right to reacquire the unit holding the intellectual property at any time. The deal is attractive, say B. Lynne Parshall, Isis chief financial officer and executive vice president, because rather than working with a pharmaceutical company, "we retain control of development of these drugs and exclusive rights to them."

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.